RDG
Q1 2026 report
Revenue
3,893.03 k PLN
— YoY
Net income
883.43 k PLN
— YoY
EBITDA
982.75 k PLN
— YoY
FCF
366.76 k PLN
— YoY
Summary
Investment thesis
- Wzrost przychodów oparty na realnym wolumenie badań: mikroelementy +37,5% liczby oznaczeń, badania molekularne ponad dwukrotnie więcej, programy NFZ +200% r/r
- Poprawa rentowności wynika częściowo z trwałej zmiany struktury kosztów (większe wykorzystanie własnej infrastruktury laboratoryjnej zamiast usług obcych)
- Bilans solidny — kapitał własny 4,61 mln zł, aktywa obrotowe 9,07 mln zł, ale największa pozycja pasywów (8,19 mln zł zobowiązań długoterminowych) ma niewyjaśniony charakter przy niemal zerowych kosztach odsetkowych
- Silna koncentracja akcjonariatu wokół założyciela (prof. Jan Lubiński kontroluje bezpośrednio i pośrednio przez GEN-PAT-MED Sp. z o.o. ponad 78% głosów) ogranicza wpływ akcjonariuszy mniejszościowych
Read the full analysis
Financial data is open to everyone. The full analysis — management verdict, commentary, risks, and the full narrative — is available after you sign up or log in.
Financials
BETA
RDG · Q1 2026
| Metric | Q1 2026 | Q1 2025 | Δ YoY | Value type | Segment | Conf. |
|---|---|---|---|---|---|---|
| Revenue | 3,893.03 | — | — | reported | — | 1.00 |
| EBITDA | 982.75 | — | — | reported | — | 1.00 |
| EBIT | 870.03 | — | — | reported | — | 1.00 |
| EBT (m PLN) | 0.77 | — | — | reported | — | 1.00 |
| Net income | 883.43 | — | — | reported | — | 1.00 |
| D&A | 112.72 | — | — | reported | — | 1.00 |
| Interest expense | 0.01 | — | — | reported | — | 1.00 |
| EBITDA margin | 25.25% | — | — | reported | — | 1.00 |
| EBIT margin | 22.35% | — | — | reported | — | 1.00 |
| EBT margin | 19.85% | — | — | reported | — | 1.00 |
| Net margin | 22.69% | — | — | reported | — | 1.00 |
| D&A margin | 2.91% | — | — | reported | — | 1.00 |
| Cash | 3,175.21 | — | — | reported | — | 1.00 |
| Equity | 4,609.23 | — | — | reported | — | 1.00 |
| Total assets | 14,851.4 | — | — | reported | — | 1.00 |
| Working capital (PLN) | 8.31 | — | — | reported | — | 1.00 |
| Current assets | 9,068.53 | — | — | reported | — | 1.00 |
| Current liabilities | 110.8 | — | — | reported | — | 1.00 |
| CFO | 515.1 | — | — | reported | — | 1.00 |
| CapEx | 148.34 | — | — | reported | — | 1.00 |
| FCF | 366.76 | — | — | reported | — | 1.00 |
| FCF conversion | 37.32% | — | — | reported | — | 1.00 |
| CFO conversion | 52.41% | — | — | reported | — | 1.00 |
| ROE | 20.99% | — | — | reported | — | 0.70 |
| ROA | 5% | — | — | reported | — | 0.60 |
| ROCE | 5.39% | — | — | reported | — | 0.60 |
| Current ratio | 81.85x | — | — | reported | — | 1.00 |
| Quick ratio | 12.58x | — | — | reported | — | 0.90 |
| Cash ratio | 4.47x | — | — | reported | — | 1.00 |
| Revenue growth (YoY) | 9.39% | — | — | reported | — | 1.00 |
| EBITDA growth (YoY) | 473.04% | — | — | reported | — | 0.80 |
| EBIT growth (YoY) | 358.63% | — | — | reported | — | 0.70 |
| Net income growth (YoY) | 396.68% | — | — | reported | — | 0.70 |
| FCF growth (YoY) | -50.51% | — | — | reported | — | 0.90 |
| EBITDA margin Δ (YoY) | 31.79 pp | — | — | reported | — | 1.00 |
| EBIT margin Δ (YoY) | 28.95 pp | — | — | reported | — | 1.00 |
| Net margin Δ (YoY) | 27.4 pp | — | — | reported | — | 1.00 |
Q1 2026 · Δ YoY
Revenue
3,893.03
—
3,893.03
—
- Q1 2025
- —
EBITDA
982.75
—
982.75
—
- Q1 2025
- —
EBIT
870.03
—
870.03
—
- Q1 2025
- —
EBT
(m PLN)
0.77
—
0.77
—
- Q1 2025
- —
Net income
883.43
—
883.43
—
- Q1 2025
- —
D&A
112.72
—
112.72
—
- Q1 2025
- —
Interest expense
0.01
—
0.01
—
- Q1 2025
- —
EBITDA margin
25.25%
—
25.25%
—
- Q1 2025
- —
EBIT margin
22.35%
—
22.35%
—
- Q1 2025
- —
EBT margin
19.85%
—
19.85%
—
- Q1 2025
- —
Net margin
22.69%
—
22.69%
—
- Q1 2025
- —
D&A margin
2.91%
—
2.91%
—
- Q1 2025
- —
Cash
3,175.21
—
3,175.21
—
- Q1 2025
- —
Equity
4,609.23
—
4,609.23
—
- Q1 2025
- —
Total assets
14,851.4
—
14,851.4
—
- Q1 2025
- —
Working capital
(PLN)
8.31
—
8.31
—
- Q1 2025
- —
Current assets
9,068.53
—
9,068.53
—
- Q1 2025
- —
Current liabilities
110.8
—
110.8
—
- Q1 2025
- —
CFO
515.1
—
515.1
—
- Q1 2025
- —
CapEx
148.34
—
148.34
—
- Q1 2025
- —
FCF
366.76
—
366.76
—
- Q1 2025
- —
FCF conversion
37.32%
—
37.32%
—
- Q1 2025
- —
CFO conversion
52.41%
—
52.41%
—
- Q1 2025
- —
ROE
20.99%
—
20.99%
—
- Q1 2025
- —
ROA
5%
—
5%
—
- Q1 2025
- —
ROCE
5.39%
—
5.39%
—
- Q1 2025
- —
Current ratio
81.85x
—
81.85x
—
- Q1 2025
- —
Quick ratio
12.58x
—
12.58x
—
- Q1 2025
- —
Cash ratio
4.47x
—
4.47x
—
- Q1 2025
- —
Revenue growth (YoY)
9.39%
—
9.39%
—
- Q1 2025
- —
EBITDA growth (YoY)
473.04%
—
473.04%
—
- Q1 2025
- —
EBIT growth (YoY)
358.63%
—
358.63%
—
- Q1 2025
- —
Net income growth (YoY)
396.68%
—
396.68%
—
- Q1 2025
- —
FCF growth (YoY)
-50.51%
—
-50.51%
—
- Q1 2025
- —
EBITDA margin Δ (YoY)
31.79 pp
—
31.79 pp
—
- Q1 2025
- —
EBIT margin Δ (YoY)
28.95 pp
—
28.95 pp
—
- Q1 2025
- —
Net margin Δ (YoY)
27.4 pp
—
27.4 pp
—
- Q1 2025
- —